CALA
Income statement / Annual
Last year (2022), Calithera Biosciences, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, Calithera Biosciences, Inc.'s net income was -$18.87 M.
See Calithera Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$9.75 M |
$0.00 |
$0.00 |
$22.25 M |
$25.96 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.39 M
|
$1.43 M
|
$1.87 M
|
$1.85 M
|
$0.00
|
$0.00
|
$297,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$1.39 M
|
$8.32 M
|
-$1.87 M
|
-$1.85 M
|
$22.25 M
|
$25.96 M
|
-$297,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0.85
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$28.53 M
|
$53.46 M
|
$71.02 M
|
$76.29 M
|
$66.20 M
|
$43.11 M
|
$27.75 M
|
$23.75 M
|
$16.37 M
|
$9.90 M
|
| General & Administrative Expenses |
$13.54 M
|
$20.85 M
|
$20.37 M
|
$16.61 M
|
$13.34 M
|
$12.53 M
|
$10.59 M
|
$9.07 M
|
$5.35 M
|
$2.48 M
|
| Selling & Marketing Expenses |
-$1.39 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.16 M
|
$20.85 M
|
$20.37 M
|
$16.61 M
|
$13.34 M
|
$12.53 M
|
$10.59 M
|
$9.07 M
|
$5.35 M
|
$2.48 M
|
| Other Expenses |
$0.00
|
$50.88 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9,000.00
|
$1,000.00
|
| Operating Expenses |
$40.69 M
|
$74.31 M
|
$91.39 M
|
$92.90 M
|
$79.54 M
|
$55.64 M
|
$38.33 M
|
$32.82 M
|
$21.72 M
|
$12.38 M
|
| Cost And Expenses |
$42.07 M
|
$74.31 M
|
$91.39 M
|
$92.90 M
|
$79.54 M
|
$55.64 M
|
$38.33 M
|
$32.82 M
|
$21.72 M
|
$12.38 M
|
| Interest Income |
$0.00
|
$345,000.00
|
$1.25 M
|
$3.04 M
|
$2.65 M
|
$1.86 M
|
$330,000.00
|
$175,000.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.39 M
|
$1.43 M
|
$1.87 M
|
$1.85 M
|
$505,000.00
|
$365,000.00
|
$297,000.00
|
$404,000.00
|
$361,000.00
|
$281,000.00
|
| EBITDA |
-$38.27 M |
-$115.43 M |
-$88.27 M |
-$88.02 M |
-$57.28 M |
-$29.69 M |
-$37.71 M |
-$32.24 M |
-$21.35 M |
-$12.10 M |
| EBITDA Ratio |
0
|
-1.4
|
0
|
0
|
-2.57
|
-1.14
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-11.84
|
0
|
0
|
-2.57
|
-1.14
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.42 M
|
$345,000.00
|
$1.25 M
|
$3.04 M
|
$2.65 M
|
$1.86 M
|
$330,000.00
|
$175,000.00
|
$9,000.00
|
$1,000.00
|
| Income Before Tax |
-$39.65 M
|
-$115.09 M
|
-$90.14 M
|
-$89.86 M
|
-$54.63 M
|
-$27.83 M
|
-$38.00 M
|
-$32.64 M
|
-$21.71 M
|
-$12.38 M
|
| Income Before Tax Ratio |
0
|
-11.8
|
0
|
0
|
-2.45
|
-1.07
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$20.78 M
|
$50.25 M
|
-$1.61 M
|
-$3.51 M
|
-$3.16 M
|
-$365,000.00
|
-$297,000.00
|
-$404,000.00
|
-$361,000.00
|
$0.00
|
| Net Income |
-$18.87 M
|
-$165.34 M
|
-$88.52 M
|
-$86.35 M
|
-$51.47 M
|
-$27.83 M
|
-$38.00 M
|
-$32.64 M
|
-$21.71 M
|
-$12.38 M
|
| Net Income Ratio |
0
|
-16.96
|
0
|
0
|
-2.31
|
-1.07
|
0
|
0
|
0
|
0
|
| EPS |
-7.94 |
-44.77 |
-25.73 |
-36.5 |
-28.12 |
-16.89 |
-39.01 |
-36.18 |
-93.34 |
-31.36 |
| EPS Diluted |
-7.94 |
-44.77 |
-25.73 |
-36.5 |
-28.12 |
-16.89 |
-39.01 |
-36.18 |
-93.34 |
-31.36 |
| Weighted Average Shares Out |
$4.99 M
|
$3.69 M
|
$3.44 M
|
$2.37 M
|
$1.83 M
|
$1.65 M
|
$974,300.00
|
$902,250.00
|
$232,600.00
|
$394,693.00
|
| Weighted Average Shares Out Diluted |
$4.99 M
|
$3.69 M
|
$3.44 M
|
$2.37 M
|
$1.83 M
|
$1.65 M
|
$974,300.00
|
$902,250.00
|
$232,600.00
|
$394,693.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
